Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza
JAMA Network Open · 22.05.2025 · 8 (5) · e2511764
DOI: 10.1001/jamanetworkopen.2025.11764 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Network Open, online erschienen am 22.05.2025. Verfasst von Liang En Wee und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infectious Diseases, Singapore. Hauptthemen laut MEDLINE: COVID-19, Respiratory Syncytial Virus Infections, Hospitalization, Influenza, Human. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Respiratory viral infections (RVIs) are associated with elevated cardiovascular risk; however, less is known about cardiac complications after hospitalization for respiratory syncytial virus (RSV) vs other vaccine-preventable RVIs (COVID-19 or influenza).
Objective
To compare the risk of acute cardiovascular complications in adults hospitalized for RSV vs COVID-19 or influenza. Design, Setting, and Participants This population-based cross-sectional study, conducted before RSV vaccination rollout in Singapore, assessed all adults hospitalized for RSV or influenza (January 1, 2017, to June 30, 2024) and all adults hospitalized for COVID-19 during Omicron XBB/JN.1 transmission (January 1, 2023, to June 30, 2024). Exposure Hospitalization for RSV, influenza (vaccinated or unvaccinated), or COVID-19 (boosted [≥3 vaccine doses] or unboosted [<3 vaccine doses]). Main Outcomes and Measures Cardiovascular events during RSV, influenza, or COVID-19 hospitalization, defined as any cardiac, cerebrovascular, or thrombotic event, occurring from admission until discharge or death. Odds of any cardiovascular event (RSV vs COVID-19 or RSV vs influenza) and severe RVI (intensive care unit admission) with or without an acute cardiovascular event were estimated using multivariate logistic regression, adjusted for sociodemographic and clinical characteristics.
Results
A total of 32 960 RVI hospitalizations (mean [SD] patient age, 66.58 [18.99] years; 17 056 [51.7%] female) were included (2148 for RSV, 14 389 for influenza, and 16 423 for COVID-19). Of the 2148 patients hospitalized for RSV, 234 (10.9%) had an acute cardiovascular event. Higher odds of any acute cardiovascular event (adjusted odds ratio [AOR], 1.31; 95% CI, 1.12-1.54) as well as other individual cardiac events were observed in RSV hospitalizations vs boosted COVID-19 (dysrhythmia: AOR, 1.52; 95% CI, 1.19-1.94; heart failure: AOR, 1.75; 95% CI, 1.30-2.35). Similarly, higher odds of any acute cardiovascular event (AOR, 1.58; 95% CI, 1.24-2.01) as well as dysrhythmias or heart failure were observed in patients hospitalized for RSV vs unboosted COVID-19. Odds of a cardiovascular event were not significantly different in RSV vs influenza, except among contemporaneous hospitalizations after the pandemic (2023-2024), where odds of heart failure (AOR, 2.09; 95% CI, 1.21-3.59) were significantly higher in RSV hospitalizations vs vaccine-breakthrough influenza hospitalizations. Occurrence of a cardiovascular event was associated with greater odds of severe RSV requiring intensive care unit admission (AOR, 2.36; 95% CI, 1.21-4.62). Conclusions and Relevance In this cross-sectional study, 1 in 10 patients hospitalized for RSV had a concurrent acute cardiovascular event. Odds of cardiac events were significantly higher in RSV vs COVID-19 hospitalizations in both vaccine-boosted and unboosted individuals. In contemporaneous hospitalizations for RSV or influenza after the pandemic (2023-2024), odds of heart failure were significantly higher in RSV hospitalizations vs vaccine-breakthrough influenza hospitalizations. These findings suggest that patients with preexisting cardiovascular risk should consider vaccination against RVIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Centre for Infectious Diseases, Singapore.
- Duke-NUS Graduate Medical School, National University of Singapore, Singapore.
- Department of Infectious Diseases, Singapore General Hospital, Singapore.
- Department of Infection Prevention and Epidemiology, Singapore General Hospital, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Ministry of Health, Singapore.
Zitieren
APA
Wee, L. E., Lim, J. T., Ho, R. W. L., Chiew, C. J., Lye, D. C. B., & Tan, K. B. (2025). Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza. JAMA Network Open, 8(5), e2511764. https://doi.org/10.1001/jamanetworkopen.2025.11764
Vancouver
Wee LE, Lim JT, Ho RWL, Chiew CJ, Lye DCB, Tan KB. Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza. JAMA Network Open. 2025;8(5):e2511764. doi:10.1001/jamanetworkopen.2025.11764
BibTeX
@article{Wee2025,
author = {Wee, Liang En and Lim, Jue Tao and Ho, Reen Wan Li and Chiew, Calvin J and Lye, David Chien Boon and Tan, Kelvin Bryan},
title = {Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {5},
pages = {e2511764},
doi = {10.1001/jamanetworkopen.2025.11764}
}
EUVIMED